Melody.education: Educational programs on Nonalcoholic Steatohepatitis (NASH) and Nonalcoholic Fatty Liver Disease (NAFLD)

About Melody.education: Educational programs on Nonalcoholic Steatohepatitis (NASH) and Nonalcoholic Fatty Liver Disease (NAFLD)

www.Melody.education is the premier, online central source and community wherein multidisciplinary healthcare providers deliver and experience the most up-to-date information, data and resources on Nonalcoholic Steatohepatitis (NASH) and Nonalcoholic Fatty Liver Disease (NAFLD). With our Clinical Experts Faculty we produce: Webconferences, Strategies for Optimal Outcomes, Case Studies, Audience Questions and Faculty Answers.

Publisher

Melody.education

Category

health & fitness

Language

en

Explicit

No

First episode

24 Nov 2022

Latest episode

9 May 2024

Latest episodes

8 episodes in the feed.

1. 

   9 May 2024

   Prof Michael Trauner presents: Emerging Role of the Hepatic Thyroid Hormone Pathway in the Pathophysiology of NASH as presented at EASL ‘23: Welcome and Introduction

   Part 1: Emerging Role of the Hepatic Thyroid Hormone Pathway in the Pathophysiology of NASH as presented at EASL ‘23: Welcome and Introduction with Prof Michael Trauner

2. 

   9 May 2024

   Prof Jörn Schattenberg presents: Emerging Role of the Hepatic Thyroid Hormone Pathway in the Pathophysiology of NASH as presented at EASL ‘23: NASH: A Growing Unmet Therapeutic Need

   Part 2: Emerging Role of the Hepatic Thyroid Hormone Pathway in the Pathophysiology of NASH as presented at EASL ‘23: NASH: A Growing Unmet Therapeutic Need with Prof Jörn Schattenberg

3. 

   9 May 2024

   Prof Meena Bansal, MD presents: Emerging Role of the Hepatic Thyroid Hormone Pathway in the Pathophysiology of NASH as presented at EASL ‘23: The Underestimated Importance of Thyroid Hormone Pathway in the Pathophysiology of NASH

   Part 3: Emerging Role of the Hepatic Thyroid Hormone Pathway in the Pathophysiology of NASH as presented at EASL ‘23: The Underestimated Importance of Thyroid Hormone Pathway in the Pathophysiology of NASH with Prof Meena Bansal, MD

4. 

   9 May 2024

   Prof Michael Trauner presents: Emerging Role of the Hepatic Thyroid Hormone Pathway in the Pathophysiology of NASH as presented at EASL ‘23: Closing

   Part 4: Emerging Role of the Hepatic Thyroid Hormone Pathway in the Pathophysiology of NASH as presented at EASL ‘23: Closing with Prof Michael Trauner

5. 

   2 May 2024

   Scott Isaacs, MD, FACE, FACP and Barton Isaac, PharmD present: NASH Patient Identification, Referral and Management in Endocrinology and Hepatology Practices

   NASH Patient Identification, Referral and Management in Endocrinology and Hepatology Practices with Scott Isaacs, MD, FACE, FACP and Barton Isaac, PharmD

6. 

   24 Nov 2022

   Keith Miller, PhD presents: Disease Overview of Nonalcoholic Steatohepatitis (NASH): The Active, Progressive Form of Nonalcoholic Fatty Liver Disease (NAFLD): Introduction

   Part 1: Disease Overview of Nonalcoholic Steatohepatitis (NASH): The Active, Progressive Form of Nonalcoholic Fatty Liver Disease (NAFLD): Introduction with Keith Miller, PhD

7. 

   24 Nov 2022

   Christina Hanson, MS, FNP presents: Disease Overview of Nonalcoholic Steatohepatitis (NASH): The Active, Progressive Form of Nonalcoholic Fatty Liver Disease (NAFLD): Definitions and Epidemiology; Pathophysiology; Natural History of the Disease; Morbidity and Mortality

   Part 2: Disease Overview of Nonalcoholic Steatohepatitis (NASH): The Active, Progressive Form of Nonalcoholic Fatty Liver Disease (NAFLD): Definitions and Epidemiology; Pathophysiology; Natural History of the Disease; Morbidity and Mortality with Christina Hanson, MS, FNP

8. 

   24 Nov 2022

   Ann Moore, FNP-C presents: Disease Overview of Nonalcoholic Steatohepatitis (NASH): The Active, Progressive Form of Nonalcoholic Fatty Liver Disease (NAFLD): Identifying Risk Factors; Patient Identification; Patient Perspective

   Part 3: Disease Overview of Nonalcoholic Steatohepatitis (NASH): The Active, Progressive Form of Nonalcoholic Fatty Liver Disease (NAFLD): Identifying Risk Factors; Patient Identification; Patient Perspective with Ann Moore, FNP-C

Reach and audience

Public platform figures. Ratings count people who left a rating, not total listeners.

Apple Podcasts (US)

3.7 / 5

3 ratings